Imperagen raises – Imperagen, a 2021 biotech spinout, has raised a £5 million seed round to make enzyme engineering faster and more reliable using quantum-physics simulation, AI models, and closed-loop automation.
A lab bench is a familiar place for enzyme engineering: tweak a mutation, test it, repeat. Imperagen’s pitch is that the cycle is too slow and too costly—and that it’s possible to start with physics, not guesswork.
On Thursday. Imperagen announced a £5 million ( $6.7 million ) seed round led by PXN Ventures. with participation from IQ Capital and Northern Gritstone. The company was founded in 2021 by Manchester Institute of Biotechnology scientists Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond, and it spun out of the university.
Imperagen says its goal is straightforward, but the work underneath is anything but: improve enzyme engineering so it becomes faster, more efficient, and less costly than the slower, more physical, trial-and-error-focused process used now.
At the center of the approach is a three-step system meant to replace large swaths of lab trial-and-error. First, the company uses a quantum physics-based simulation to predict how enzyme variants might behave. Instead of testing mutations one by one. it explores millions of mutations on a computer using advanced quantum physics modeling. Imperagen says.
Next, it translates those predictions into custom AI models. Those models are trained on the enzyme problems Imperagen wants to solve.
Then comes the loop that turns simulation into usable science: robots and automation generate experimental data, and that data is fed back into the AI model in a process the company calls closed-loop simulation. The idea is to keep the models grounded in reality as the system learns.
Enzymes matter far beyond the lab. They are essential to drug development, and they are used across industries including food, biofuels, and agriculture. Imperagen also points to sustainability-focused work where enzyme technology—and the AI built around it—could help make industrial production more sustainable.
The race is attracting attention from other startups as well, including Biomatter, Cradle Bio, and Absci.
The funding arrives alongside leadership change. Imperagen said Guy Levy-Yurista will assume the role of CEO. Speaking to TechCrunch. Levy-Yurista argued that enzyme engineering is falling short: even many new AI-powered technologies can pass trial and error. but fail when they’re put into practice on an industrial scale.
Levy-Yurista said the company’s technology is meant to help it overcome that gap. calling for an enzyme engineering process that’s “faster. more reliable. and more commercially accessible. helping companies bring better bio-based products to market without the long timelines and uncertainty that have traditionally held the field back.”.
Levy-Yurista brings a background in AI, life sciences, and enterprise technology. The company says the founders will remain at Imperagen. and that Levy-Yurista was brought in to help build out its new technologies. including a vertical AI infrastructure for biocatalysis — a process that accelerates chemical reactions using natural catalysts like enzymes. His mandate also includes scaling the startup’s AI strategy, commercial models, and industrial partnerships.
Imperagen has raised £8.5 million ( $11.42 million ) in funding to date. The fresh capital will be used to hire more AI specialists, put toward research and development, expand its experimental lab capabilities, and build a go-to-market function within the next two years.
Levy-Yurista said the company hopes wider use of engineered enzymes will help industries reliably produce products “cleaner, safer and better for people and the planet,” while still making commercial sense for companies that adopt them.
For Imperagen, the test won’t be the simulation itself. It will be whether the loop—quantum modeling feeding AI, AI guiding experiments, and automation keeping the data coming—can deliver the kind of enzyme engineering that works not just in a trial, but in a factory.
Imperagen enzyme engineering quantum physics simulation AI models closed-loop simulation seed round PXN Ventures IQ Capital Northern Gritstone biocatalysis biotech startup
So basically they’re trying to hack enzymes with computers? Wild.
£5 million seed round doesn’t sound like that much when they want to change “millions of mutations” or whatever. Also do they mean quantum like on a gaming PC? Lol.
Wait, “start with physics, not guesswork” sounds good but I’m confused how it’s not still guesswork if an AI is predicting. Like if the simulation is wrong then they’re just automating wrong results faster, right? I don’t know.
Closed-loop automation… so robots do the trial and error and the scientists just watch? That seems like it could be good for drugs, but also kinda scary because biotech already has enough issues. Enzymes are used in food too so I’m trying to picture what changes in grocery ingredients after this. Also 2021 spinout, so they’ve been working on it forever and now only getting £5m? Idk.